Wild-type p53 activates transcription in vitro
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 protein is an important determinant in human cancer and regulates the growth of cells in culture. It is known to be a sequence-specific DNA-binding protein with a powerful activation domain, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tumor-suppressor protein, p53, plays a central role in the cellular response to UV-induced DNA damage/repair (13).”
From Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism (2010) · cites this paper as [13]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,825
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Research works printed but not linked: 7
- O'Rourke, R. W. et al. Oncogene 5, 1829–1832 (1990).
- Zhu, H., Roy, A. L., Roeder, R. G. & Prywes, R. New Biologist 3, 455–464 (1991).
- Kern, S. E. et al. Oncogene 6, 131–136 (1991).
- Fried, M. & Prives, C. Cancer Cells 4, 1–16 (1986).
- Soussi, T., Caron de Fromentel, C. & May, P. Oncogene 5, 945–952 (1990).
- Murakami, Y., Asano, M., Satake, M. & Ito, Y. Oncogene 5, 5–14 (1990).
- Zambetti, G. P. et al. Genes Dev. (in the press).
Cited by
Items 401–500 of 578
Beachy, T. M., Cole, S., Cavender, J. F., & Tevethia, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.7.3145-3157.2002 · Cited by 26
“In each of these cases, the transcriptional transactivating capacity of p53 is inhibited (12, 21, 35, 37, 39).”
BackgroundInvolvement of the p53/p21 complex in p53-dependent gene expression
Kim, U., Kim, K. S., Park, J., & Um, H. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.07.022 · Cited by 25
Connections between 3′ end processing and DNA damage response: Ten years later
Murphy, M. R., & Kleiman, F. E. (2019) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1571 · Cited by 21
Ishioka, C., Shimodaira, H., Englert, C., Shimada, A., Osada, M., Jia, L.-Q., Suzuki, T., Gamo, M., & Kanamaru, R. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6216 · Cited by 26
Ranki, A., Lassus, J., & Niemi, K. ‐. (1995) · Acta Dermato Venereologica · doi:10.2340/0001555575180186 · Cited by 21
Lack of MDM2 amplification in human leukaemia
Ridge, S. A., Dyer, M. J. S., Greaves, M. F., & Wiedemann, L. M. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04754.x · Cited by 21
Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder
Mellon, K., WILKINSON, S., VICKERS, J., Robinson, M., Shenton, B. K., & Neal, D. E. (1994) · British Journal of Urology · doi:10.1111/j.1464-410x.1994.tb07637.x · Cited by 21
Mouse DDA3 gene is a direct transcriptional target of p53 and p73
Hsieh, S., Lo, P., & Wang, F.-F. (2002) · Oncogene · doi:10.1038/sj.onc.1205417 · Cited by 23
“…is activated and renders the cells unable to progress through the cell cycle. p53 is a transcription factor capable of activating the transcription of genes carrying distinct p53 binding motif of the consensus sequence 5'-PuPuPuC(A/T)(T/ A)GPyPyPy-3' (Farmer et al., 1992; El-Deiry et al., 1992).”
BackgroundG�hring, U.-J., Scharl, A., Heckel, C., Ahr, A., & Crombach, G. (1995) · Archives of Gynecology and Obstetrics · doi:10.1007/bf01314642 · Cited by 20
“This protein binds to the DNA in a specific manner and acts as a promoter for the transcription of a gene sequence which has an inhibitory effect on cell growth [11, 12, 18, 24].”
BackgroundP53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas
Pápai, Z., FÉja, C. N., Hanna, E., Sztán, M., Oláh, E., & Szendrői, M. (1997) · Pathology & Oncology Research · doi:10.1007/bf02893346 · Cited by 19
“The location of the primary minor in descending order of frequency was the distal femur 43% (n = 9), proximal tibia 33% ( 7 ), proximal humerus 19% (4) and sacrum 4% (1).”
BackgroundUV-inducible base excision repair of oxidative damaged DNA in human cells
Kassam, S. N., & Rainbow, A. J. (2008) · Mutagenesis · doi:10.1093/mutage/gen054 · Cited by 19
“The p53 protein is a tumor suppressor responsible for the regulation of genes to prevent uncontrolled cell growth (13,14).”
BackgroundTransformation and Tumorigenesis Mediated by the Adenovirus E1A and E1B Oncogenes
Ricciardi, R. P. (1995) · Infectious agents and pathogenesis · doi:10.1007/978-1-4899-1100-1_11 · Cited by 20
Hyperphosphorylation of p53 induced by benzene, toluene, and chloroform
Dees, C., & Travis, C. C. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90365-4 · Cited by 19
Kamel, D., Soini, Y., Nuorva, K., P��kk�, P., Khalifa, A., Mangoud, A. M. M., & V�h�kangas, K. (1994) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00190555 · Cited by 19
“The p53 gene encodes a nuclear phosphoprotein which plays an important role in the control of DNA transcription and replication (Steinmeyer et al. 1990; Farmer et al. 1992; Vogelstein and Kinzler 1992).”
BackgroundVprBP/DCAF1 regulates p53 function and stability through site-specific phosphorylation
Ghate, N. B., Kim, S., Mehmood, R., Shin, Y., Kim, K., & An, W. (2023) · Oncogene · doi:10.1038/s41388-023-02685-8 · Cited by 21
Mdm2, p53, p21 and pAKT protein pathways in benign neoplasms of the salivary gland
Marques, Y., de Lima, M. D. D. M., Júnior, S. D. M. A., Soares, F. A., de Araújo, V. C., Júnior, D. D. S. P., & Mantesso, A. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.11.013 · Cited by 20
Tierney, L. A., Hahn, F. F., & Lechner, J. F. (1996) · Radiation Research · doi:10.2307/3579173 · Cited by 18
Lassus, P., Bertrand‐Gaday, C., Zugasti, O., Chambon, J., Soussi, T., Mathieu-Mahul, D., & Hibner, U. (1999) · Oncogene · doi:10.1038/sj.onc.1202841 · Cited by 20
“Moreover, this point mutant has a strong dominant negative e ect on the wild type p53 (Farmer et al., 1992; Kern et al., 1992), implying that its capacity to form hetero-oligomers with the wild type protein is intact.”
BackgroundProtein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
Marques, M. A., de Andrade, G. C., Silva, J. L., & de Oliveira, G. A. P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.944955 · Cited by 17
“References included in the timeline but not mentioned in the text: (Michalovitz et al., 1990; Farmer et al., 1992; Selivanova et al., 1997; Verhaegh et al., 1998; Foster et al., 1999; Stommel et al., 1999; Martinez et al., 2002; Yin et al., 2002; Lambert et al., 2009; Hu et al., 2010a; Adriaens et al., 2016; Kadosh et…”
BackgroundChen, G., DenBoer, L. M., & Shin, J. A. (2008) · BioTechniques · doi:10.2144/000112901 · Cited by 17
Double-edged role of PML nuclear bodies during human adenovirus infection
Hofmann, S., Stubbe, M., Mai, J., & Schreiner, S. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198280 · Cited by 20
p53 Amino Acids 339–346 Represent the Minimal p53 Repression Domain
Hong, T.-M., Chen, J. J. W., Peck, K., Yang, P., & Wu, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008231200 · Cited by 17
Triad 1 induces apoptosis by p53 activation
Jung, J. H., Lee, S., Bae, S., Lee, S., Park, I., Jin, Y.-W., Lee, J. H., & An, S. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.03.011 · Cited by 16
“Both transcriptional-dependent and -independent activation of p53 is sufficient for triggering apoptosis [2,3].”
Backgroundp53 elevation in human cells halt SV40 infection by inhibiting T-ag expression
Drayman, N., Ben-nun-Shaul, O., Butin‐Israeli, V., Srivastava, R., Rubinstein, A. M., Mock, C. S., Elyada, E., Ben‐Neriah, Y., Lahav, G., & Oppenheim, A. (2016) · Oncotarget · doi:10.18632/oncotarget.10769 · Cited by 18
“As a transcription factor [8] p53 activates or represses a variety of target genes, leading to DNA repair, cell-cycle arrest, senescence, or apoptosis [9, 10].”
BackgroundMolecular genetics of acute lymphoblastic leukemia
Ferrando, A. A., Rubnitz, J. E., & Look, A. T. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.011 · Cited by 16
Biological significance and molecular mechanisms of p53-induced apoptosis
Bedi, A., & Mookerjee, B. (1998) · APOPTOSIS · doi:10.1023/a:1009648824027 · Cited by 17
Bjørling-Poulsen, M., Siehler, S. Y., Wiesmüller, L., Meek, D. W., Niefind, K., & Issinger, O. (2005) · Oncogene · doi:10.1038/sj.onc.1208762 · Cited by 16
“The TGCCT repeat from the ribosomal gene cluster, a p53-binding site (Kern et al., 1991; Farmer et al., 1992), was [32P]-labeled by PCR, purified and quantified as described previously (Boehden et al., 2004).”
MethodInteraction of HPV E6 with p53 and associated proteins
Crook, T., & Vousden, K. H. (1994) · Biochemical Society Transactions · doi:10.1042/bst0220052 · Cited by 16
Focal adhesion kinase-regulated signaling events in human cancer
Fu, W., Hall, J. E., & Schaller, M. D. (2012) · BioMolecular Concepts · doi:10.1515/bmc-2011-0049 · Cited by 21
“p53 is a tumor suppressor that functions as a transcription factor (61) .”
BackgroundPeacock, J. W., & Benchimol, S. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06357.x · Cited by 16
The p53 Tumor Suppressor Gene: Structure, Function and Mechanism of Action
Choisy, C., Reisdorf, P., & Yonish-Rouach, E. (1999) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69184-6_8 · Cited by 19
Translational research in lung cancer
Chen, Y., Okunieff, P., & Ahrendt, S. A. (2003) · Seminars in Surgical Oncology · doi:10.1002/ssu.10039 · Cited by 14
“In response to DNA damage by ionizing radiation and a variety of chemical agents or carcinogens, p53 induces cells to repair damage or promote apoptosis (Yin et al. 1992; Hartwell 1992; Farmer et al. 1992).”
BackgroundKwon, Y. V., Shin, B. S., & Chung, I. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002081200 · Cited by 14
Soulié, P., Poupon, M., Remvikos, Y., Dutrillaux, B., & Muleris, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202336 · Cited by 14
“Indeed, these mutations may di erently a ect normal p53 functions (Farmer et al., 1992; Hinds et al., 1990; Hupp et al., 1993; Pocard et al., 1996).”
BackgroundAlteration of c-fos gene methylation in human gliomas
Uyeno, S., Komura, J., Tawa, R., Aoki, Y., Nata, M., Sasano, H., Nakura, H., SAGISAKA, K., Sakurai, H., Kayama, T., et al. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199606)16:2<115::aid-mc8>3.0.co;2-h · Cited by 4
Wang, M., Yang, Z., Song, Y., Wei, P., Ishimwe, N., Wang, L., Zhang, H., Jing, M., Gao, M., Wen, L., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.07.057 · Cited by 14
Rizzo, M. G., Soddu, S., Tibursi, G., Calabretta, B., & Sacchi, A. (1993) · Clinical & Experimental Metastasis · doi:10.1007/bf00132980 · Cited by 13
“In spite of the fact that p53 protein is a specific DNA-binding factor [4, 5], and that mutations may cause suppression of its activity [6], the mechanism by which the p53 protein acts as tumor suppressor is not well understood [7].”
BackgroundRunnebaum, I. B., Tong, X. W., Möbus, V. J., Kieback, D., Rosenthal, H. E., & Kreienberg, R. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00953-8 · Cited by 13
Duan, W., Gao, L., Wu, X., Hade, E. M., Gao, J., Ding, H., Barsky, S. H., Otterson, G. A., & Villalona-Calero, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005563 · Cited by 13
“One possibility is that mutant p53 inhibits the sequence-specific DNA-binding and transactivation functions of wild-type p53 in a ‘‘dominant-negative’’ manner by forming hetero-oligomeric complexes with it [10,11].”
Backgroundp53 immunohistochemical expression: messages in cervical carcinogenesis
Cheah, P., & Looi, L. (2002) · Pathology · doi:10.1080/003130202760120472 · Cited by 13
Boehden, G. S., Baumann, C., Siehler, S. Y., & Wiesmüller, L. (2005) · Oncogene · doi:10.1038/sj.onc.1208592 · Cited by 13
“Clearly, the striking difference between the results obtained with RGC and its mutated version indicated that stable complex formation between p53 and its binding sequence RGC is the critical determinant of this effect (Kern et al., 1991, 1992; Farmer et al., 1992).”
MethodResultNucleotide sequence of the ovine P53 tumor-suppressor cDNA and its genomic organization
Dequiedt, F., Kettmann, R., Burny, A., & Willems, L. (1995) · DNA sequence · doi:10.3109/10425179509030976 · Cited by 13
Transcription Factors as Molecular Mediators in Cell Death
Soares, H. D., Curran, T., & MORGAN, J. I. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44408.x · Cited by 13
Katara, R., Mir, R. A., Shukla, A. A., Tiwari, A., Singh, N., & Chauhan, S. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.103 · Cited by 12
“Tumor-derived mutant p53 can form a complex with wt p53 and block the p53-mediated transcription of target genes (Farmer et al., 1992).”
BackgroundLevesque, M. A., Diamandis, E. P., Yu, H., & Sutherland, D. J. A. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666062 · Cited by 12
“The action of the expressed 53 kDa nuclear phosphoprotein remains unclear, although roles in control of DNA replication [28], and transcriptional activation [29] leading to growth arrest [30] or programmed cell death after DNA damage [31], have been postulated.”
BackgroundLanfrancone, L., Pelicci, G., & Pelicci, P. G. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90099-x · Cited by 18
Hydroxyurea (HU)-induced apoptosis in the mouse fetal lung
Woo, G., Bak, E., Nakayama, H., & Doi, K. (2005) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.02.007 · Cited by 11
Recent Patents on Cell Cycle Regulatory Proteins
Chulu, J. L. C., & Liu, H. (2009) · Recent Patents on Biotechnology · doi:10.2174/187220809787172614 · Cited by 11
Giant leap for p53, small step for drug design
Anderson, M. E., & Tegtmeyer, P. (1995) · BioEssays · doi:10.1002/bies.950170103 · Cited by 11
Nucleotide sequence of the bovine P53 tumor-suppressor cDNA
Dequiedt, F., Willems, L., Burny, A., & Kettmann, R. (1995) · DNA sequence · doi:10.3109/10425179509030977 · Cited by 11
Cyclin E enhances P53‐mediated transactivation
Segawa, K., Hokuto, I., Minowa, A., Ohyama, K., & Takano, T. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80238-p · Cited by 12
Toshihisa Ito, S. F. (2001) · Acta Oto-Laryngologica · doi:10.1080/00016480127367 · Cited by 11
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models
Ramelow, J., Brooks, C. D., Gao, L., Almiman, A., Williams, T. M., Villalona-Calero, M. A., & Duan, W. (2020) · BMC Cancer · doi:10.1186/s12885-020-07212-6 · Cited by 11
Cagle, P. T., Fraire, A. E., Greenberg, S. D., Cox, A., & Brown, R. W. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90315-9 · Cited by 10
Martin, K. R., Saulnier, M., Kari, F. W., Barrett, J. C., & French, J. E. (2002) · Nutrition and Cancer · doi:10.1207/s15327914nc431_7 · Cited by 10
Genomic Organization and Chromosomal Mapping of the Bovine Fas/APO-1 Gene
Yoo, J., STONE, R. T., Kappes, S. M., Toldo, S. S., Fries, R., & Beattie, C. W. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.377 · Cited by 10
“…product p53 up-regulates the expression of hFas (Owen-Schaub et al, 1995). p53 has been shown to regulate gene expression by DNA sequence-specific interactions (El-Deiry et al, 1992; Farmer et al, 1992) and also by interacting with other DNA-binding proteins (Agoff et al, 1993; Mack et al, 1993).”
Photoreversion of ultraviolet induced apoptosis in Rat Kangaroo cells
Miyaji, E. N., & Menck, C. F. M. (1996) · APOPTOSIS · doi:10.1007/bf01321022 · Cited by 8
Gottifredi, V., Peschiaroli, A., Fimia, G. M., & Maione, R. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.14.2397 · Cited by 9
Recessive oncogenes: Current status
Gao, X., & Honn, K. V. (1995) · Pathology & Oncology Research · doi:10.1007/bf02893578 · Cited by 9
Albor, A., Laborda, J., & Notario, V. (1994) · Molecular Carcinogenesis · doi:10.1002/mc.2940110309 · Cited by 9
Green, D. R., Bañuls, M. P., Gearing, A. J. H., Needham, L. A., White, M., & Clements, J. M. (1994) · Endothelium · doi:10.3109/10623329409088475 · Cited by 9
Zerrahn, J., Tiemann, F., & Deppert, W. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6781-6789.1996 · Cited by 9
“In line with this assumption is the observation that the DNA-binding and transactivation properties of wild-type (wt) p53 complexed with large T are greatly reduced (2, 3, 24, 43, 61, 86).”
BackgroundRidgway, P., Soussi, T., & Braithwaite, A. W. (1994) · Journal of Virology · doi:10.1128/jvi.68.11.7178-7187.1994 · Cited by 9
Mukherjee, J. J., Kumar, S., Gocinski, R., & Williams, J. (2011) · Chemical Research in Toxicology · doi:10.1021/tx100440c · Cited by 8
p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture
Pozzo, A. R., Booth, S., Yu, P. L. I., Singh, M., Selivanova, G., & Mai, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020598 · Cited by 8
Li, H., Wang, J., Huang, K., Zhang, T., Gao, L., Yang, S., Yi, W., Niu, Y., Liu, H., Wang, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648045 · Cited by 9
Lung pathology: the molecular genetics of non-small cell lung cancer
Fong, K. M., Zimmerman, P. V., & Smith, P. J. (1995) · Pathology · doi:10.1080/00313029500169173 · Cited by 8
The P53 Tumor Suppressor Protein
Appella, E., Sakaguchi, K., Sakamoto, H., Lewis, M. S., Omichinski, J. G., Gronenborn, A. M., Clore, G. M., & Anderson, C. W. (1995) · Springer eBooks · doi:10.1007/978-1-4899-1031-8_36 · Cited by 8
Prognostic and predictive value of p53 and p21 in breast cancer
Elledge, R. M., & Allred, D. C. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5195-9_14 · Cited by 9
Transformation by Polyomaviruses: Role of Tumor Suppressor Proteins
Simmons, D. T. (1995) · Infectious agents and pathogenesis · doi:10.1007/978-1-4899-1100-1_3 · Cited by 9
Prasad, K. A. N., & Church, J. G. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6212 · Cited by 8
Cyclin D1 and prognosis in human breast cancer
Gillett, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., & Barnes, D. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960422)69:2<92::aid-ijc4>3.0.co;2-q · Cited by 327
Concepts in B cell acute lymphoblastic leukemia pathogenesis
Garcia, C., Miller, M. D., & Witkowski, M. T. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae015 · Cited by 12
Transcriptional Responses to Damage Created by Ionizing Radiation: Molecular Sensors
Davis, T. W., Meyers, M., Patten, C. W.-V., Sharda, N. N., Yang, C., Kinsella, T. J., & Boothman, D. A. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-455-9_14 · Cited by 12
p53 Overexpression in squamous cell carcinoma of the esophagus
Baron, P. L., Gates, C. E., Reed, C. E., Dikeman, R. L. D., Drosieko, J. J., Passmore, R. N., Bromberg, J. S., & Willingham, M. C. (1997) · Annals of Surgical Oncology · doi:10.1007/bf02316809 · Cited by 7
“This binding may inactivate the function of the normal protein and can explain why mutant p53 is able to transform cells in the presence of wild-type protein ( 34 ).”
BackgroundThe role of DNA repair in the prevention of cancer
Hall, M., & Johnson, R. T. (1996) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(96)00001-5 · Cited by 8
Lin, S., YANG, Y.-C., JUNG, J.-H., & Jh, T. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.793 · Cited by 7
Dasgupta, P. S. (1991) · New York University Press eBooks · Cited by 6
Yang, D., Qi, Y., Chen, Q., Wang, Z., Jin, X., Gao, J., Fu, J., Xiao, X., & Zhou, Z. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9503-9 · Cited by 6
“The P53 protein is a transcriptional transactivator [ 2 , 3] that binds to specific short genomic DNA sequences [4‐6] that fit a consensus sequence with variable extent [7], thus induces expression of specific target genes.”
BackgroundFundamentals of Transcription Factors and their Impact on Pancreatic Development and Cancer
Fernández-Zapico, M. E., Bramati, P. S., Zakaria, S., Kaczynski, J., & Urrutia, R. A. (2003) · Pancreatology · doi:10.1159/000071765 · Cited by 6
Lassus, J., & Ranki, A. (1996) · Experimental Dermatology · doi:10.1111/j.1600-0625.1996.tb00097.x · Cited by 6
Numerical and Experimental Analysis of the p53-mdm2 Regulatory Pathway
van Leeuwen, I. M. M., Sanders, I., Staples, O. D., Laín, S., & Munro, A. J. (2010) · Lecture notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering · doi:10.1007/978-3-642-14859-0_20 · Cited by 6
Malignant Epithelial Neoplasms of the Large Bowel
Walsh, S. V., & Carey, F. A. (2012) · Wiley eBooks · doi:10.1002/9781118399668.ch38 · Cited by 8
Morrison, B. W. (1994) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30185-0 · Cited by 6
Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma
Anselmo, N. P., REY, J. A., Almeida, L. O., Cust�dio, A. C., Almeida, J. R. W., Clara, C., dos Santos, M. J., & Casartelli, C. (2009) · Genetics and Molecular Research · doi:10.4238/vol8-4gmr631 · Cited by 5
Malkin, D. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_11 · Cited by 6
Umeda, J., Itoi, T., Sofuni, A., Itokawa, F., Kurihara, T., Tsuchiya, T., Ishii, K., Tsuji, S., Ikeuchi, N., Tanaka, R., et al. (2013) · Journal of Oncology · doi:10.1155/2013/170625 · Cited by 5
“However, from the point of cost benefit, it is not practical to perform these tests for all patients as screening.”
BackgroundWachtel, S. S., Wachtel, G., SHULMAN, L. P., Phillips, O. P., Miller, B. E., & Photopulos, G. J. (1994) · Journal of the Society for Gynecologic Investigation · doi:10.1177/107155769400100310 · Cited by 5
Robbins, P. (1996) · International Journal of Surgical Pathology · doi:10.1177/106689699600400206 · Cited by 5
“Transcription of genes containing specific p53 responsive elements is enhanced by wild type p53 [25].”
BackgroundEffects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies
Cook, J. L., Zhang, Z., Alam, J., & Ré, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1202566 · Cited by 9
“A number of reports (Raycroft et al., 1991; Santhanam et al., 1991; Farmer et al., 1992; Mack *Correspondence: JL Cook Received 17 April 1998; revised 22 September 1998; accepted 3 November 1998 Oncogene (1999) 18, 2373± 2379 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00…”
BackgroundInfluentialp53: A target for new anticancer drugs or a target for old drugs?
Brown, R. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058614 · Cited by 7
The role of p53 in the DNA damage-related ubiquitylation of S2P RNAPII
Borsos, B. N., Pantazi, V., Páhi, Z. G., Majoros, H., Újfaludi, Z., Berzsenyi, I., & Pankotai, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267615 · Cited by 4
“However, a novel role of p53 in transcription elongation has been recently revealed in yeast and human models [10–14].”
Duan, W., Gao, L., Kalvala, A., Aguila, B., Brooks, C., Mo, X. M., Ding, H., Shilo, K., Otterson, G. A., & Villalona-Calero, M. A. (2019) · International Journal of Cancer · doi:10.1002/ijc.32279 · Cited by 4
Ellison, V., Annor, G. K., Freedman, C., Xiao, G., Lundine, D., Freulich, E., Prives, C. L., & Bargonetti, J. (2021) · Oncotarget · doi:10.18632/oncotarget.27975 · Cited by 6
“They also inhibit activation of transcription target genes associated with the initiation of growth arrest and apoptosis [11, 14, 15].”
BackgroundLow grade amplification of MDM2 gene in a subset of human breast cancers without p53 alterations
Takami, K., Inui, H., Nagayama, K., Watatani, M., Yasutomi, M., Kurahashi, H., Mori, T., Takai, S., & Nishisho, I. (1994) · Breast Cancer · doi:10.1007/bf02967038 · Cited by 4
Oxidative Stress, Antioxidant Status, and Redox Signaling in Carcinogenesis
Pande, D., Negi, R., Karki, K., Khanna, S., Dwivedi, U. S., Khanna, R. S., & Khanna, H. D. (2014) · Springer eBooks · doi:10.1007/978-81-322-2035-0_22 · Cited by 4
Absence of p53 mutation in Japanese patients with malignant thyroid lymphoma
IYOTA, K., Takeda, K., Matsuzuka, F., Okabayashi, T., Morita, S., Kuma, K., & Hashimoto, K. (1994) · Journal of Endocrinological Investigation · doi:10.1007/bf03347774 · Cited by 4
Suppression of Cellular Proliferation Using p53 DNA Recognition Site-Related Oligonucleotides
Ré, R. N., & Cook, J. L. (1996) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)41641-6 · Cited by 4
Human Papillomaviruses, Tumour Suppressor Genes and Cervical Cancer
Inman, G. J., Cook, I. D., & Lau, R. K. W. (1993) · International Journal of STD & AIDS · doi:10.1177/095646249300400302 · Cited by 5
Metadata
- Authors
- Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C.
- Affiliations
- Columbia University (US)
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2063158632
- Cited by
- 579
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 7
- FWCI
- 38.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, transcriptional activation, wild-type p53, mutant p53, SV40 large T antigen, DNA-binding proteins, tumour suppressor, protein-protein interaction, transcriptional repression
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, DNA Mutational Analysis, DNA-Binding Proteins, Gene Expression Regulation, HeLa Cells, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Structure-Activity Relationship, Transcription Factors, Transcription, Genetic, Tumor Suppressor Protein p53, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.